Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.

Håkansson KEJ, Rasmussen LJH, Godtfredsen NS, Tupper OD, Eugen-Olsen J, Kallemose T, Andersen O, Ulrik CS.

Respir Res. 2019 Nov 15;20(1):258. doi: 10.1186/s12931-019-1234-4.

2.

Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People.

Rasmussen LJH, Moffitt TE, Arseneault L, Danese A, Eugen-Olsen J, Fisher HL, Harrington H, Houts R, Matthews T, Sugden K, Williams B, Caspi A.

JAMA Pediatr. 2019 Nov 4:1-11. doi: 10.1001/jamapediatrics.2019.3875. [Epub ahead of print]

3.

Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial.

Pedersen LR, Olsen RH, Anholm C, Astrup A, Eugen-Olsen J, Fenger M, Simonsen L, Walzem RL, Haugaard SB, Prescott E.

Cardiovasc Diabetol. 2019 Oct 1;18(1):127. doi: 10.1186/s12933-019-0934-x.

4.

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.

Schultz M, Rasmussen LJH, Høi-Hansen T, Kjøller E, Jensen BN, Lind MN, Ravn L, Kallemose T, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen KK.

Dis Markers. 2019 May 19;2019:3403549. doi: 10.1155/2019/3403549. eCollection 2019.

5.

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency.

Höybye C, Faseh L, Himonakos C, Pielak T, Eugen-Olsen J.

Endocr Connect. 2019 Jun 1;8(6):772-779. doi: 10.1530/EC-19-0159.

6.

Risk assessment models for potential use in the emergency department have lower predictive ability in older patients compared to the middle-aged for short-term mortality - a retrospective cohort study.

Schultz M, Rasmussen LJH, Carlson N, Hasselbalch RB, Jensen BN, Usinger L, Eugen-Olsen J, Torp-Pedersen C, Rasmussen LS, Iversen KK.

BMC Geriatr. 2019 May 16;19(1):134. doi: 10.1186/s12877-019-1154-7.

7.

Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial.

Schultz M, Rasmussen LJH, Kallemose T, Kjøller E, Lind MN, Ravn L, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen K.

Scand J Trauma Resusc Emerg Med. 2019 Apr 11;27(1):43. doi: 10.1186/s13049-019-0621-7.

8.

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.

Rotbain Curovic V, Theilade S, Winther SA, Tofte N, Eugen-Olsen J, Persson F, Hansen TW, Jeppesen J, Rossing P.

Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.

PMID:
30885954
9.

Healthy lifestyles reduce suPAR and mortality in a Danish general population study.

Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C, Eugen-Olsen J.

Immun Ageing. 2019 Jan 22;16:1. doi: 10.1186/s12979-018-0141-8. eCollection 2019.

10.

Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.

Törnkvist PBS, Haupt TH, Rasmussen LJH, Ladelund S, Toft U, Pisinger C, Eugen-Olsen J.

Br J Nutr. 2019 Mar;121(6):699-708. doi: 10.1017/S0007114518003720. Epub 2019 Jan 10.

PMID:
30626457
11.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression.

Hoenigl M, Moser C, Funderburg N, Bosch R, Kantor A, Zhang Y, Eugen-Olsen J, Finkelman M, Reiser J, Landay A, Moisi D, Lederman MM, Gianella S; ACTG NWCS 411 study team.

Clin Infect Dis. 2018 Nov 12. doi: 10.1093/cid/ciy966. [Epub ahead of print]

12.

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.

Alstrup M, Meyer J, Schultz M, Rasmussen LJH, Rasmussen LS, Køber L, Forberg JL, Eugen-Olsen J, Iversen K.

World J Surg. 2019 Mar;43(3):780-790. doi: 10.1007/s00268-018-4841-1.

PMID:
30390135
13.

A simple clinical assessment is superior to systematic triage in prediction of mortality in the emergency department.

Iversen AKS, Kristensen M, Østervig RM, Køber L, Sölétormos G, Lundager Forberg J, Eugen-Olsen J, Rasmussen LS, Schou M, Iversen KK.

Emerg Med J. 2019 Feb;36(2):66-71. doi: 10.1136/emermed-2016-206382. Epub 2018 Oct 16.

PMID:
30327415
14.

Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.

Rasmussen LJH, Ladelund S, Haupt TH, Ellekilde GE, Eugen-Olsen J, Andersen O.

Crit Care Med. 2018 Dec;46(12):1961-1968. doi: 10.1097/CCM.0000000000003441.

15.

Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).

Schultz M, Rasmussen LJH, Andersen MH, Stefansson JS, Falkentoft AC, Alstrup M, Sandø A, Holle SLK, Meyer J, Törnkvist PBS, Høi-Hansen T, Kjøller E, Jensen BN, Lind M, Ravn L, Kallemose T, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen KK.

Scand J Trauma Resusc Emerg Med. 2018 Aug 28;26(1):69. doi: 10.1186/s13049-018-0539-5.

16.

Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.

Blauenfeldt T, Petrone L, Del Nonno F, Baiocchini A, Falasca L, Chiacchio T, Bondet V, Vanini V, Palmieri F, Galluccio G, Casrouge A, Eugen-Olsen J, Albert ML, Goletti D, Duffy D, Ruhwald M.

Front Immunol. 2018 Jul 5;9:1456. doi: 10.3389/fimmu.2018.01456. eCollection 2018.

17.

Histological and Molecular Adipose Tissue Changes Are Related to Metabolic Syndrome Rather Than Lipodystrophy in Human Immunodeficiency Virus-Infected Patients: A Cross-Sectional Study.

Langkilde A, Tavenier J, Danielsen AV, Eugen-Olsen J, Therkildsen C, Jensen FK, Henriksen JH, Langberg H, Steiniche T, Petersen J, Holck S, Andersen O.

J Infect Dis. 2018 Aug 24;218(7):1090-1098. doi: 10.1093/infdis/jiy284.

PMID:
29788076
18.

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.

Godtfredsen NS, Jørgensen DV, Marsaa K, Ulrik CS, Andersen O, Eugen-Olsen J, Rasmussen LJH.

Respir Res. 2018 May 21;19(1):97. doi: 10.1186/s12931-018-0803-2.

19.

Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood.

Rasmussen LJH, Moffitt TE, Eugen-Olsen J, Belsky DW, Danese A, Harrington H, Houts RM, Poulton R, Sugden K, Williams B, Caspi A.

J Child Psychol Psychiatry. 2019 Feb;60(2):199-208. doi: 10.1111/jcpp.12928. Epub 2018 May 9.

PMID:
29741788
20.

Effect of simvastatin and ezetimibe on suPAR levels and outcomes.

Hodges GW, Bang CN, Forman JL, Olsen MH, Boman K, Ray S, Kesäniemi YA, Eugen-Olsen J, Greve AM, Jeppesen JL, Wachtell K.

Atherosclerosis. 2018 May;272:129-136. doi: 10.1016/j.atherosclerosis.2018.03.030. Epub 2018 Mar 16.

PMID:
29602140
21.

suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.

Meyer J, Alstrup M, Rasmussen LJH, Schultz M, Ladelund S, Haupt TH, Tingleff J, Iversen K, Eugen-Olsen J.

Scand J Trauma Resusc Emerg Med. 2018 Feb 1;26(1):11. doi: 10.1186/s13049-018-0478-1.

22.

SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis.

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Kesäniemi AY, Jeppesen JL, Wachtell K.

Open Heart. 2018 Jan 13;5(1):e000743. doi: 10.1136/openhrt-2017-000743. eCollection 2018.

23.

Routine blood tests are associated with short term mortality and can improve emergency department triage: a cohort study of >12,000 patients.

Kristensen M, Iversen AKS, Gerds TA, Østervig R, Linnet JD, Barfod C, Lange KHW, Sölétormos G, Forberg JL, Eugen-Olsen J, Rasmussen LS, Schou M, Køber L, Iversen K.

Scand J Trauma Resusc Emerg Med. 2017 Nov 28;25(1):115. doi: 10.1186/s13049-017-0458-x.

24.

Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.

Kirkegaard-Klitbo DM, Langkilde A, Mejer N, Andersen O, Eugen-Olsen J, Benfield T.

J Infect Dis. 2017 Oct 17;216(7):819-823. doi: 10.1093/infdis/jix266.

PMID:
29099961
25.

Metabolic biomarkers and gallstone disease - a population-based study.

Shabanzadeh DM, Skaaby T, Sørensen LT, Eugen-Olsen J, Jørgensen T.

Scand J Gastroenterol. 2017 Nov;52(11):1270-1277. doi: 10.1080/00365521.2017.1365166. Epub 2017 Aug 11.

PMID:
28799434
26.

Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.

Rasmussen LJH, Schultz M, Gaardsting A, Ladelund S, Garred P, Iversen K, Eugen-Olsen J, Helms M, David KP, Kjaer A, Lebech AM, Kronborg G.

Int J Cancer. 2017 Jul 1;141(1):191-199. doi: 10.1002/ijc.30732. Epub 2017 Apr 24.

27.

Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.

Langkilde A, Jakobsen TL, Bandholm TQ, Eugen-Olsen J, Blauenfeldt T, Petersen J, Andersen O.

Osteoarthritis Cartilage. 2017 Aug;25(8):1265-1273. doi: 10.1016/j.joca.2017.03.008. Epub 2017 Mar 16.

28.

Erratum to: Association between routine laboratory tests and long-term mortality among acutely admitted older medical patients: a cohort study.

Klausen HH, Petersen J, Bandholm T, Juul-Larsen HG, Tavenier J, Eugen-Olsen J, Andersen O.

BMC Geriatr. 2017 Mar 15;17(1):67. doi: 10.1186/s12877-017-0463-y. No abstract available.

29.

Association between routine laboratory tests and long-term mortality among acutely admitted older medical patients: a cohort study.

Klausen HH, Petersen J, Bandholm T, Juul-Larsen HG, Tavenier J, Eugen-Olsen J, Andersen O.

BMC Geriatr. 2017 Mar 1;17(1):62. doi: 10.1186/s12877-017-0434-3. Erratum in: BMC Geriatr. 2017 Mar 15;17 (1):67.

30.

Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR.

Rudolf F, Wagner AJ, Back FM, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):67-72. doi: 10.5588/ijtld.16.0404.

PMID:
28157467
31.

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.

von Scholten BJ, Persson F, Rosenlund S, Eugen-Olsen J, Pielak T, Faber J, Hansen TW, Rossing P.

Diabetes Obes Metab. 2017 Jun;19(6):901-905. doi: 10.1111/dom.12884. Epub 2017 Mar 2.

PMID:
28105731
32.

Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers.

Renault KM, Carlsen EM, Hædersdal S, Nilas L, Secher NJ, Eugen-Olsen J, Cortes D, Olsen SF, Halldorsson TI, Nørgaard K.

Int J Obes (Lond). 2017 Apr;41(4):598-605. doi: 10.1038/ijo.2017.9. Epub 2017 Jan 17.

PMID:
28093573
33.

Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.

Rasmussen LJ, Ladelund S, Haupt TH, Ellekilde G, Poulsen JH, Iversen K, Eugen-Olsen J, Andersen O.

Emerg Med J. 2016 Nov;33(11):769-775. doi: 10.1136/emermed-2015-205444. Epub 2016 Sep 2.

34.

SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis.

Hodges GW, Bang CN, Eugen-Olsen J, Olsen MH, Boman K, Ray S, Gohlke-Bärwolf C, Kesäniemi YA, Jeppesen JL, Wachtell K.

Can J Cardiol. 2016 Dec;32(12):1462-1469. doi: 10.1016/j.cjca.2016.04.012. Epub 2016 May 3.

PMID:
27499378
35.

Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial.

Sandø A, Schultz M, Eugen-Olsen J, Rasmussen LS, Køber L, Kjøller E, Jensen BN, Ravn L, Lange T, Iversen K.

Scand J Trauma Resusc Emerg Med. 2016 Aug 5;24:100. doi: 10.1186/s13049-016-0290-8.

36.

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving HH.

J Diabetes Complications. 2016 Nov - Dec;30(8):1440-1442. doi: 10.1016/j.jdiacomp.2016.07.003. Epub 2016 Jul 16.

PMID:
27475262
37.

Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.

Lindboe JB, Langkilde A, Eugen-Olsen J, Hansen BR, Haupt TH, Petersen J, Andersen O.

Infect Dis (Lond). 2016 Nov-Dec;48(11-12):829-37. doi: 10.1080/23744235.2016.1201722. Epub 2016 Jul 15.

PMID:
27417288
38.

Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.

Knudsen TB, Ertner G, Petersen J, Møller HJ, Moestrup SK, Eugen-Olsen J, Kronborg G, Benfield T.

J Infect Dis. 2016 Oct 15;214(8):1198-204. doi: 10.1093/infdis/jiw263. Epub 2016 Jun 28.

PMID:
27354366
39.

suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease.

Theilade S, Rossing P, Eugen-Olsen J, Jensen JS, Jensen MT.

Eur J Endocrinol. 2016 Jun;174(6):745-53. doi: 10.1530/EJE-15-0986. Epub 2016 Mar 7.

PMID:
26951602
40.

Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.

Pedersen LR, Olsen RH, Anholm C, Walzem RL, Fenger M, Eugen-Olsen J, Haugaard SB, Prescott E.

Atherosclerosis. 2016 Mar;246:221-8. doi: 10.1016/j.atherosclerosis.2016.01.001. Epub 2016 Jan 13.

PMID:
26803431
41.

Plasma suPAR is lowered by smoking cessation: a randomized controlled study.

Eugen-Olsen J, Ladelund S, Sørensen LT.

Eur J Clin Invest. 2016 Apr;46(4):305-11. doi: 10.1111/eci.12593. Epub 2016 Feb 19.

PMID:
26799247
42.

Letters to the Editor: Genetic polymorphism and soluble urokinase plasminogen activator receptor regulation.

Rasmussen LJ, Haupt TH, Andersen O, Eugen-Olsen J.

FASEB J. 2015 Dec;29(12):4757-8. doi: 10.1096/fj.15-1201LTE. No abstract available.

PMID:
26626707
43.

The formation and design of the TRIAGE study--baseline data on 6005 consecutive patients admitted to hospital from the emergency department.

Plesner LL, Iversen AK, Langkjær S, Nielsen TL, Østervig R, Warming PE, Salam IA, Kristensen M, Schou M, Eugen-Olsen J, Forberg JL, Køber L, Rasmussen LS, Sölétormos G, Pedersen BK, Iversen K.

Scand J Trauma Resusc Emerg Med. 2015 Dec 1;23:106. doi: 10.1186/s13049-015-0184-1.

44.

suPAR: The unspecific marker for disease presence, severity and prognosis.

Eugen-Olsen J, Giamarellos-Bourboulis EJ.

Int J Antimicrob Agents. 2015 Dec;46 Suppl 1:S33-4. doi: 10.1016/j.ijantimicag.2015.10.011. Epub 2015 Oct 31. Review.

PMID:
26603640
45.

Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.

Rasmussen LJ, Knudsen A, Katzenstein TL, Gerstoft J, Obel N, Jørgensen NR, Kronborg G, Benfield T, Kjaer A, Eugen-Olsen J, Lebech AM.

HIV Med. 2016 May;17(5):350-7. doi: 10.1111/hiv.12315. Epub 2015 Sep 14.

46.

Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.

Langkilde A, Petersen J, Henriksen JH, Jensen FK, Gerstoft J, Eugen-Olsen J, Andersen O.

Immun Ageing. 2015 Aug 4;12:9. doi: 10.1186/s12979-015-0036-x. eCollection 2015.

47.

suPAR: A New Biomarker for Cardiovascular Disease?

Hodges GW, Bang CN, Wachtell K, Eugen-Olsen J, Jeppesen JL.

Can J Cardiol. 2015 Oct;31(10):1293-302. doi: 10.1016/j.cjca.2015.03.023. Epub 2015 Mar 25. Review.

PMID:
26118447
48.

Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE.

Int J Cardiol. 2015 Apr 1;184:631-6. doi: 10.1016/j.ijcard.2015.03.041. Epub 2015 Mar 4.

PMID:
25771228
49.

Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.

Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Schutte AE.

Hypertens Res. 2015 Jun;38(6):439-44. doi: 10.1038/hr.2015.22. Epub 2015 Mar 5.

PMID:
25740290
50.

Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.

Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, Pisinger C, Eugen-Olsen J.

Biomark Insights. 2014 Dec 16;9:91-100. doi: 10.4137/BMI.S19876. eCollection 2014.

Supplemental Content

Loading ...
Support Center